Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects. Ten CF subjects received single 180-mg doses of two formulations of MP-376, followed by a multiple-dose phase of 240 mg once daily for 7 days. Ser...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Antimicrobial agents and chemotherapy Ročník 55; číslo 6; s. 2636
Hlavní autori:	Geller, David E, Flume, Patrick A, Griffith, David C, Morgan, Elizabeth, White, Dan, Loutit, Jeffery S, Dudley, Michael N
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.06.2011
Predmet:	Administration, Inhalation Adolescent Adult Anti-Bacterial Agents - pharmacokinetics Area Under Curve Cross-Over Studies Cystic Fibrosis - drug therapy Female Humans Levofloxacin Male Middle Aged Ofloxacin - adverse effects Ofloxacin - pharmacokinetics Single-Blind Method Solutions
ISSN:	1098-6596, 1098-6596
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!